secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pasithea Therapeutics Corp. (KTTA)
CIK:        0001841330
Form:       8-K
Filed at:   2023-12-28T23:59:59+00:00
Accession:  0001213900-23-099115
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 3.03, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pasithea Therapeutics announces 1-for-20 reverse stock split effective January 2, 2024
--------------------------------------------------------------------------------

- Reverse split ratio of 1-for-20; authorized shares reduced from 495M to 100M.
- Effective at market open on January 2, 2024; CUSIP changes to 70261F202.
- No fractional shares issued; cash payment based on 5-day average closing price pre-split.
- All outstanding options, warrants, and convertible debt adjusted proportionately.
- Board approved the split on Dec 21; shareholders authorized at Dec 19 annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841330/000121390023099115/0001213900-23-099115-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841330/000121390023099115/ea190815-8k_pasithea.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-099115

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer